Effective July 1, 2020, the Oklahoma Health Care Authority (OHCA) has changed the billing practices for certain high-investment drugs therapies. This change will improve access to expensive yet highly impactful drug therapies for the SoonerCare population.

These high-investment drugs which are “carved out” will still require a prior authorization (PA).

If the billing entity is purchasing the carve-out drug through their 340b program, then all applicable federal, supplemental, and value based rebates will be collected from the billing entity.

Please see Provider Letter 2020-04 for more information.

**Drugs currently carved out:**

- Kymriah® (tisagenlecleucel)
- Luxturna® (voretigene neparvovec-ryzl)
- Spinraza® (nusinersen)
- Yescarta® (axicabtagene ciloleucel)
- Zolgensma® (onasemnogene abeparvovec-xioi)

If you have any questions, please contact the pharmacy helpdesk at (800) 522-0114, option 4 or (405) 522-6205, option 4.

Thank you for your continued support and the services you provide to SoonerCare members.